May 05, 2026 | Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off

Myqorzo hits both endpoints in ACACIA-HCM, opening amultibillion-dollar HCM market Camzyos can't reach. Plus: Pfizer scraps its last CD47 program from the $2.3B Trillium acquisition, Madrigal licenses Arrowhead's PNPLA3 siRNA for up to $1B, and the Supreme Court keeps mifepristone in play.Visit us at www.thepharamcloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Cytokinetics,Myqorzo, aficamten, hypertrophic cardiomyopathy, HCM, ACACIA-HCM, Pfizer,Trillium Therapeutics, CD47, Madrigal, Arrowhead, MASH, PNPLA3, Rezdiffra,mifepristone, Supreme Court, Auvelity, Axsome, Viridian, Tepezza, Intercept,BioNTech, Jakafi XR, Incyte, Leqembi, Sanofi, Passage Bio, Gilead, Arcellx,Novartis, J&J, Amgen